Methamphetamine Abuse Impacts Glial Metabolism

N. Sailasuta1, O. Abulseoud1, K. Harris1, and M. Hernandez2,3
1Clinical MR Spectroscopy, Huntington Medical Research Institutes, Pasadena, CA, United States, 2University of Southern California, Keck School of Medicine, Los Angeles, CA, United States, 3Rudi Schulte Research Institute, Santa Barbara, CA, United States

Purpose: Use 13C MRS to define specific glial metabolic rate in humans recovering from methamphetamine abuse.

Background: Drug abuse severely impacts cognitive functions associated with frontal lobe structures. Conventional PET and fMRI have been used to map the anatomical extent of abnormalities but throw little light on the possible underlying mechanism of drug addiction, craving or recovery. 13C MRS provides unique distinction between neuronal and glial compartments and, with recent technical advances (1), can now safely be applied to address the question of glial dysfunction in frontal brain of human subjects.

Human Subjects, Patients and Methods: Ten human subjects were recruited for the 13C MRS study, 5 recently (3 – 8 weeks since last use) abstinent methamphetamine dependent (AMD) and 5 age and gender matched normal controls. DVM-IV, SCID and neuropsychological as well as complete drug history were provided. The 10 subjects received sterile intravenous 1-13C acetate (IND 59,960) 3 gm/kg body weight over 1 hour. Using GE 1.5 Tesla broad-band clinical MR scanner with a conforming dual tuned proton/carbon RF coil applied to the forehead, low power NOE 13C spectra were acquired in 6 minute blocks for 120 minutes. Data was processed as previously described to yield peak intensities for glutamate (182ppm) and glutamine C5 (178ppm), glutamine+glutamate C1 (175ppm) and bicarbonate (161ppm) (2). For the present study, the flux rate of 1-13C acetate to 13C bicarbonate = glial TCA cycle rate was calculated and expressed as µmoles/g/minute.

Results: Localizer MRI from the dual tuned RF coil defined the volume of interest of approximately 100cc to include prefrontal cortex and frontal white matter in approximately equal proportions, which did not differ between AMD and Controls. Glial TCA cycle rate for frontal brain in normal subjects was 0.11±0.01 µmoles/g/minute. The rate in AMD was only half of that in normal subjects (0.04±0.01 µmoles/min/g: P 0.001).

Figure 1, left, shows MRI of the frontal brain. Comparison of 13C MRS spectra of HCO3 and Cr plus phosphocreatine at 120 min after the infusion in control (left) and AMD (right) subject is shown in figure 2 (middle figure). The un-enriched Cr + PCr peak intensities indicate that their concentration is very similar while substantial differences in HCO3 peak intensities was observed between control and AMD subject. Logarithmic fits of the averaged % fractional enrichment of HCO3 (%E) is plotted as a function of time after start of the infusion shown in figure 3 (right). %E in AMD (lower trace) was shown to be lower than the controls (upper trace) with significant P values calculated between 7-40min (P=0.002), 60 min (P<0.001), and 120 min (P<0.001) after start of the infusion.

Discussion and Conclusions:
Drug abuse, a major neuropsychiatric challenge of our times has resisted a clear definition in neurochemical terms. The present study represents a ‘first’ at several levels: First clinical 13C MRS study of frontal brain in humans. First demonstration that in vivo glial activity is under metabolic control. First evidence that methamphetamine abuse may impact the glutamate neurotransmitter system. The 13C MRS technique appears to be robust and reproducible and therefore suited to more detailed longitudinal studies in patients necessary to unravel the complex cycle of drug abuse, craving, relapse and recovery.